• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Artificial Organs >Engineering Vascularized Bone Graft With Osteogenic and Angiogenic Lineage Differentiated Bone Marrow Mesenchymal Stem Cells
【24h】

Engineering Vascularized Bone Graft With Osteogenic and Angiogenic Lineage Differentiated Bone Marrow Mesenchymal Stem Cells

机译：用成骨和血管生成的分化骨髓间充质干细胞工程化血管化的骨移植。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Tissue-engineered bone provides a promising method for the rehabilitation of acquired bone defects and congenital deformities. However, generating a vascular supply to the engineered graft remains a major challenge. We report a novel strategy to engineer vascularized bone grafts with osteogenic and angiogenic lineage differentiated marrow mesenchymal stem cells (MSCs). MSCs were expanded to form an osteogenic cell sheet using a continuous culture method and a scraping technique under osteogenic culture conditions. Another portion of MSCs was directed to differentiate into highly proliferative endothelial progenitor cells (EPCs), which were then seeded onto the cell sheets. Cell sheet-EPC complexes were implanted subcutaneously in nude mice. Cell sheets without EPCs were also implanted as a control. The mice were sacrificed, and the samples were harvested for evaluation consisting of micro-CT scanning, histological analysis and scanning electronic microscopy 4 and 8weeks after implantation. The results showed that cell sheets were composed of viable cells and extracellular matrix and showed apparent mineralization. The obtained EPCs could express the specific antigen marker of CD31 and form capillary-like structures in vitro. The osteogenic cell sheet-EPC complexes yielded well-vascularized bone grafts 4 and 8weeks after implantation. Both bone density and vascular density were significantly higher in the cell sheet-EPC complex group than in the control group. The results demonstrated that the introduction of EPCs could not only generate a vascular network but also increase bone formation for cell sheet-based bone engineering. These findings suggest that the strategy of engineering bone grafts with osteogenic and angiogenic lineage differentiated MSCs has great potential for clinical applications to repair large bone defects.
机译：组织工程化的骨为获得性骨缺损和先天性畸形的康复提供了一种有前途的方法。然而，为工程移植物产生血管供应仍然是主要挑战。我们报告了一种新的策略来工程化成骨和血管生成的分化骨髓间充质干细胞（MSCs）的血管化的骨移植。在成骨培养条件下，使用连续培养方法和刮擦技术将MSCs扩增形成成骨细胞片。 MSC的另一部分被定向分化为高度增殖的内皮祖细胞（EPC），然后将其接种到细胞片上。将细胞片-EPC复合物皮下植入裸鼠中。没有EPC的细胞片也被植入作为对照。处死小鼠，并在植入后4周和8周收集样品以进行评估，包括显微CT扫描，组织学分析和扫描电子显微镜。结果表明，细胞片由活细胞和细胞外基质组成，并表现出明显的矿化作用。所获得的EPCs可以表达CD31的特异性抗原标记，并在体外形成毛细管样结构。成骨细胞片-EPC复合物在植入后4和8周产生了血管良好的骨移植物。细胞片-EPC复合物组的骨密度和血管密度均显着高于对照组。结果表明，EPC的引入不仅可以生成血管网络，而且可以增加基于细胞片的骨工程学的骨形成。这些发现表明，用成骨和血管生成谱系分化的MSC对骨移植物进行工程改造的策略在修复大型骨缺损的临床应用中具有巨大潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号